Abstract:6028 Background: The role of a triple combination of gemcitabine (chemotherapy) plus apatinib (anti-VEGF) and toripalimab (anti-PD-1) (GAT) in recurrent/metastatic nasopharyngeal carcinoma is unclear. Methods: Between August 2019 and April 2020, 54 patients with recurrent or metastatic NPC were screened, of whom 41 eligible patients were enrolled and received study treatment. Patients were treated with gemcitabine (1000 mg/m 2 ) on days 1 and 8 once every 3 weeks for a maximum of 6 cycles plus toripalimab (240 mg) on day 1 once every 3 weeks and apatinib (orally administered at 250 mg) once a day until disease progression, death, dose-limiting toxicities, or at the patient’s request to stop. The primary endpoint was the safety. The secondary endpoints included the objective response rate (ORR) and progression-free survival (PFS). Results: By the data cutoff date, the median follow-up time was 13.4 months. G3-4 hematologic, gastrointestinal and kidney toxicities were observed in no more than 3 (3/41, 7.3%) patients, while G3-4 nasopharyngeal wall necrosis was observed in 9 (9/41, 21.9%) patients. High-risk factors for nasopharyngeal necrosis, included repeated radiotherapy and an interval of less than 12 months from the last radiotherapy. Among all 41 patients, the ORR was 90.2% (95% CI: 76.9%-97.2%). The median PFS was 13.93 months (95% CI: NR-NR), and the 12-month PFS rate was 72.0% (95% CI: 57.1%-86.9%). A substantial increase of CD28+ and ICOS+ CD4+/CD8+ T cells and a decrease of PD1+ CD4+/CD8+ T cells were observed in the peripheral blood after the GAT treatment. 11q13.3 amplification and MRGPRF high expression in tumors correlated with poor PFS from the triple combination therapy. NPCs with 11q13.3 amplification was characterized by high epithelial mesenchymal transition (EMT) and immune suppressive transcriptional signatures. Furthermore, serial circulating tumor DNA (ctDNA) sequencing could predict PFS outcomes to combination therapy. Conclusions: The triple combination of GAT exhibits a promising antitumor activity and manageable toxicities in patients with recurrent/metastatic NPC. Patients with repeated radiotherapy and an interval of less than 12 months from the last radiotherapy should be carefully selected for antiangiogenic therapies. An integrated genomic and transcriptional analyses may aid to identify the beneficial patient populations in response to this novel combination therapy. Clinical trial information: NCT04073784.

Inhibition of cyclin-dependent kinases by AT7519 enhances nasopharyngeal carcinoma cell response to chemotherapy

Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro.

Casein kinase 1α-dependent inhibition of Wnt/β-catenin selectively targets nasopharyngeal carcinoma and increases chemosensitivity

Polo‐like Kinase 1 Inhibitor NMS‐P937 Represses Nasopharyngeal Carcinoma Progression Via Induction of Mitotic Abnormalities

Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway

Dual Phosphoinositide 3-Kinase/mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Has a Therapeutic Potential and Sensitizes Cisplatin in Nasopharyngeal Carcinoma.

ZD1839 and cisplatin alone or in combination for treatment of a nasopharyngeal carcinoma cell line and Xenografts.

A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma

Quercetin acts as a novel anti-cancer drug to suppress cancer aggressiveness and cisplatin-resistance in nasopharyngeal carcinoma (NPC) through regulating the yes-associated protein/Hippo signaling pathway

Tumor-specific Cytolysis Caused by an E1B55K-attenuated Adenovirus in Nasopharyngeal Carcinoma is Augmented by Cisplatin.

Induction of Cell Cycle Arrest and Apoptosis in Human Nasopharyngeal Carcinoma Cells by ZD6474, an Inhibitor of VEGFR Tyrosine Kinase with Additional Activity Against EGFR Tyrosine Kinase

Comprehensive Immune Landscape and Molecular Characteristics of Clinical Responses to Chemotherapy, Antiangiogenic Agents and PD-1 Inhibitors in Advanced Nasopharyngeal Cancer

Targeting the JAK1 /STAT3 Signaling Pathway: Entinostat as a Promising Treatment for Nasopharyngeal Carcinoma

Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1

In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma.

Heterogeneous nuclear ribonucleoprotein K is a potential target for enhancing the chemosensitivity of nasopharyngeal carcinoma

Cetuximab and Cisplatin Show Different Combination Effect in Nasopharyngeal Carcinoma Cells Lines via Inactivation of EGFR/AKT Signaling Pathway

Saucerneol Attenuates Nasopharyngeal Carcinoma Cells Proliferation and Metastasis Through Selectively Targeting Grp94

Chk1 Inhibitor Gö6976 Enhances the Sensitivity of Nasopharyngeal Carcinoma Cells to Radiotherapy and Chemotherapy in Vitro and in Vivo

PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma

Inhibition of MNK pathway sensitizes nasopharyngeal carcinoma to radiotherapy